NASDAQ OMX

Informa Pharma Intelligence's Citeline API Works with Saama to Deliver Unprecedented Insight into Clinical Trials

Dela
Citeline leveraging Saama's artificial intelligence to offer customers a complete understanding of the clinical trial landscape

LONDON, Feb. 12, 2018 (GLOBE NEWSWIRE) -- Today, Citeline, part of Informa Pharma Intelligence's suite of pharmaceutical, medtech and biomedical research and analysis solutions, and Saama Technologies, Inc., a leading clinical analytics company, announced a partnership to integrate Citeline's application programming interfaces (APIs) with Saama's artificial intelligence and deep learning solutions.

This is a strategic effort to bridge global clinical data and real-world data to improve both planning for and conducting clinical trials. Joint customers will get unparalleled insight into robust clinical trial intelligence with greater efficiency than before.

Saama is integrating with Citeline's APIs, including Trialtrove and Sitetrove, which provide users with the ability to go even deeper with search criteria and make better, more well-informed decisions, gain competitive advantage, and optimize ROI for their clinical trials. Combined with Saama's real-world analytics, mutual customers will have smarter, more streamlined and successful clinical trials.

"This partnership represents a great use case for Citeline's newly released API's," said Jason Tse, Head of Strategic Partnerships at Informa Pharma Intelligence. "We're continuing to drive innovative products alongside our partners and bridge real-world data with our clinical trial information, tackling a growing unmet need in our industry. Through this partnership, our joint customers will be able to overcome clinical development challenges, gain industry insights, and optimize trial success through multiple points of triangulation."

"The partnership between Citeline's expert clinical trial data and Saama's award-winning AI-enabled technologies, which leverage both structured and unstructured real-world data, represents the next phase of intelligent clinical trial planning and execution," said Luke Stewart, Director of Product Management at Saama.

Attendees at this week's 2018 Summit for Clinical Ops Executives (SCOPE) meeting in Orlando should visit Informa Pharma Intelligence at booth 617 and Saama at booth 316 to learn more about the partnership.

About Informa  Pharma Intelligence
Informa Pharma Intelligence powers a full suite of analysis products - Datamonitor Healthcare, Sitetrove, Trialtrove, Pharmaprojects, Medtrack, Biomedtracker, Scrip, Pink Sheet and In Vivo - to deliver the data needed by the pharmaceutical and biomedical industry to make decisions and create real-world opportunities for growth. 

With more than 500 analysts keeping their fingers on the pulse of the industry, no key disease, clinical trial, drug approval or R&D project isn't covered through the breadth and depth of data available to customers. For more information visit pharmaintelligence.informa.com

About Citeline
Citeline, part of Informa's Pharma Intelligence vertical, is the world's most comprehensive source of real-time R&D intelligence for the pharmaceutical industry, featuring an unmatched intelligence collection and enrichment of global clinical trials, clinical trial investigator profiles and drug development pipelines.

Citeline is the R&D Intelligence arm of Informa's Pharma Intelligence vertical, one of the world's leading providers of drug, device, company, clinical trial and market intelligence in the pharma and medtech markets.  For more information, visit pharmaintelligence.informa.com

About Saama
Saama Technologies is the advanced data and analytics company delivering actionable business insights for life sciences and the Global 2000. We are singularly focused on driving fast, flexible, impactful business outcomes for our clients through data and analytics. Our unique "hybrid" approach integrates focused solutions and expertise across the life sciences domain, business consulting, data science, automated data management, and big data technologies. We integrate manual and disconnected initiatives into a well-aligned roadmap facilitating the client's journey from strategy through solution implementation.

Media Contact   
Diffusion PR for Informa Pharma Intelligence 
Allie Tedone
informapharma@diffusionpr.com 
646.571.0120




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Informa Business Intelligence via Globenewswire

Om

NASDAQ OMX
NASDAQ OMX



Följ NASDAQ OMX

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från NASDAQ OMX

Quantenna's New QSR10GU-AX Plus Raises the Bar for Wi-Fi Performance and Functionality19.6.2018 14:00Pressmeddelande

SAN JOSE, Calif., June 19, 2018 (GLOBE NEWSWIRE) -- Quantenna Communications, Inc. (NASDAQ:QTNA), the innovator and global leader of high performance Wi-Fi solutions, today announced that the QSR10GU-AX Plus, a new enhanced solution targeting gateways and access points based on the draft IEEE 802.11ax standard, is now sampling to select customers. Building upon Quantenna's pioneering QSR10G-AX Wi-Fi platform, QSR10GU-AX Plus offers unique capabilities, including Adaptive 5 GHz, SuperTx and ESP, providing significant performance gains across a variety of home configurations. The QSR10GU-AX Plus can operate concurrently in both 8x8 MIMO in the 5 GHz band and 4x4 MIMO in the 2.4 GHz band supporting a total of 12 streams. Unique features of QSR10GU-AX Plus include: Dynamic switching between 8x8 MIMO and dual 4x4 MIMO in the 5 GHz band by applying adaptive algorithms, enabled by Quantenna's unique baseband and RF architecture design. This provides the end users with the best possible MIMO c

CrownBio Enters Partnership with Pierre Fabre to Accelerate Discovery and Development of Immuno-Oncology Agents19.6.2018 14:00Pressmeddelande

SAN DIEGO, June 19, 2018 (GLOBE NEWSWIRE) -- Crown Bioscience, a global drug discovery and development services company providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research, announces that it has been selected by Pierre Fabre Research Institute as one of their partners to advance their immuno-oncology drug discovery pipeline. CrownBio boasts the world's largest collection of patient-derived xenograft (PDX) models and is a leading provider of humanized solutions for immuno-oncology drug development. Leveraging these exclusive capabilities, CrownBio will engraft PDX models selected by Pierre Fabre into CD34+ humanized mouse models. These customized, humanized models will be used to accelerate Pierre Fabre's innovative immuno-oncology drug discovery pipeline. "Pierre Fabre recognizes the value of CrownBio's extensive PDX collection and their expertise in implementing innovative humanization strategies," said Nathalie Corvaia, P

Glatfelter to Acquire Georgia-Pacific's European Nonwovens Business for $185 Million19.6.2018 13:44Pressmeddelande

YORK, Pa., June 19, 2018 (GLOBE NEWSWIRE) -- June 19, 2018 - Glatfelter (NYSE:GLT), a global supplier of specialty papers and engineered materials, today announced it has signed a definitive agreement to purchase Georgia-Pacific's European nonwovens business (the "Business") for $185 million, subject to customary purchase price adjustments. The proposed transaction includes Georgia-Pacific's operations located in Steinfurt, Germany, along with sales offices located in France and Italy. The Steinfurt facility produces high-quality airlaid products for the table-top, wipes, hygiene, food pad, and other nonwoven materials markets, competing in the marketplace with nonwoven technologies and substrates, as well as other materials focused primarily on consumer based end-use applications. The Steinfurt facility is a state-of-the-art, 32,000-metric-ton-capacity manufacturing facility that employs approximately 220 people. "Glatfelter's agreement to acquire the European nonwovens business demon

Industry stakeholders partner on blockchain based margin and collateral solution19.6.2018 13:00Pressmeddelande

AMSTERDAM, the Netherlands, BRUSSELS, Belgium, LONDON and STOCKHOLM, Sweden, June 19, 2018 (GLOBE NEWSWIRE) -- ABN AMRO Clearing, EuroCCP, Euroclear and Nasdaq have completed a joint proof of concept to make the use of securities more efficient when used to cover margin calls, including after business hours, using blockchain, or distributed ledger technology (DLT). This solution addresses significant business challenges and inefficiencies related to the current provision of collateral to Central Counterparties (CCPs) and has demonstrated that a shared, resilient network can be built between collateral givers, collateral takers and intermediaries. The inefficiencies of collateral processing have been heightened as a result of recent market changes such as extended trading hours by stock exchanges and the requirement to centrally clear derivatives traded bilaterally (OTC) under the European Market Infrastructure Regulation (EMIR). Today, a CCP margin call typically needs to be covered by

Lithium Werks and Endrich agree pan-Asian battery distribution deal19.6.2018 09:00Pressmeddelande

AUSTIN, Texas, June 19, 2018 (GLOBE NEWSWIRE) -- Battery and portable power solutions group Lithium Werks B.V. has signed a strategic distribution agreement with Taipei, Taiwan-based distributor Endrich Co., Ltd to bolster its support for Asian customers. "Demand for lithium batteries from Asian customers has been strong for a long time, but even so, we've seen nothing yet. We expect an enormous uptick in demand in the years ahead," said T. Joseph Fisher III, CEO and co-founder of Lithium Werks. "With its unrivaled knowledge of Asian markets, Endrich is a trusted supplier to a number of tier-one ODMs (original design manufacturers) and OEMs (original equipment manufacturers). "Together, we will continue to develop ever closer relationships with customers in markets such as Taiwan, Japan, South Korea and, not least, China, where we are preparing to build a lithium battery giga factory," he said. "I have known Endrich for a long time, so I already know that this partnership will be benef

PubMatic Launches PubMatic Cloud to Evolve the SSP Business Model19.6.2018 09:00Pressmeddelande

New offering provides publishers and tech companies with a transparent alternative to revenue shares REDWOOD CITY, Calif., June 19, 2018 (GLOBE NEWSWIRE) -- PubMatic, the publisher-focused sell-side platform (SSP) for an open digital media future, today announced the launch of PubMatic Cloud for publishers and tech companies looking to implement and control their own programmatic technology. By accessing PubMatic's technology, global infrastructure and demand connections on a platform-as-a-service (PaaS) basis, clients are able to achieve full transparency and achieve greater control over their programmatic monetization. As programmatic trading becomes mainstream, innovations such as header bidding and fraud controls have resulted in gains for publishers. However, it has also contributed to the ballooning of infrastructure costs and overhead to manage integrations with the buy-side and third-party technology vendors as well as continuously evolving technology. The ability to keep pace

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum